Celerion Launches Electronic Laboratory Notebook
Celerion
announces implementation of the electronic laboratory notebook in its global bioanalytical network. Celerion designed and implemented
Labnotes
, a commercially available electronic laboratory notebook system to standardize bioanalytical processes and improve documentation consistency for all studies.
Clients benefit from faster access to data and improved information quality due to centralized data repositories. Real time data integrity eliminates manual calculations and sources of potential error.
The electronic laboratory notebook has built-in calculations for critical aspects of the bioanalytical workflow, standardizing everything from reference standards, to instrument and pipette calibration. The system increases consistency and significantly reduces sources of manual error. The electronic laboratory notebook is validated to OECD GLP and FDA 21 CFR Part 11 computerized system regulatory requirements.
Celerion collaborated with Laboratory Data Solutions Ltd on their Labnotes electronic laboratory notebook product. “We are delighted to have worked with Celerion on implementing the Labnotes solution” said Jeremy Cook, Director of Laboratory Data Solutions. “The team at Celerion has invested significant time in ensuring the system is completely integrated into the bioanalytical workflow..”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
